Neurocentria, Inc

Neurocentria is a late-stage biotechnology company dedicated to discovering and developing novel treatments for neurodegenerative and neuropsychiatric disorders, including ADHD, depression and Alzheimers disease. Since 2005, our team has been innovating breakthrough therapies to address the pathophysiology of these disorders, prevent their progression or even reverse their course, reduce symptoms and improve patients performance and quality of life. Currently available treatments for these disorders are acting on classical targets identified decades ago, especially for ADHD and depression, with no new approaches introduced during this time. And, too often, patients endure just as much from the side effects of their medications....

Neurodegeneration,alzheimer's disease,adhd,depression,neuroscience,drug development,translational research,biomarkers,adult attention deficit hyperactivity,cognition,mood,neuropsychiatric disorders,innovative therapeutics,synaptic function,synaptic loss reverals,cognitive function,executive dysfunction,magnesium compound,anxiety,and pharmaceutical company

Neurocentria, inc operates in the Biotechnology research industry.

Neurocentria, inc's revenue is 11m - 100m

Neurocentria, inc has 11 - 50 employees.